Assessing the inhibition efficacy of clinical drugs against the main proteases of SARS‐CoV‐2 variants and other coronaviruses

Wenlong Zhao; Cecylia S. Lupala; Shifeng Hou; Shuxin Yang; Ziqi Yan; Shujie Liao; Xuefei Li; Nan Li

doi:10.1002/qub2.60

Quant. Biol. ›› 2024, Vol. 12 ›› Issue (3) : 324 -328. DOI: 10.1002/qub2.60

COMMUNICATION

Assessing the inhibition efficacy of clinical drugs against the main proteases of SARS‐CoV‐2 variants and other coronaviruses

Author information +

History +

PDF (1080KB)

Keywords

drug resistance / enzymatic activity / main protease / SARS‐CoV‐2

Cite this article

Download citation ▾

Wenlong Zhao, Cecylia S. Lupala, Shifeng Hou, Shuxin Yang, Ziqi Yan, Shujie Liao, Xuefei Li, Nan Li. Assessing the inhibition efficacy of clinical drugs against the main proteases of SARS‐CoV‐2 variants and other coronaviruses. Quant. Biol., 2024, 12(3): 324-328 DOI:10.1002/qub2.60

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Li P , Wang Y , Lavrijsen M , Lamers MM , de Vries AC , Rottier RJ , et al. SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell Res. 2022; 32 (3): 322- 4.

[2]	Owen DR , Allerton CMN , Anderson AS , Aschenbrenner L , Avery M , Berritt S , et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021; 374 (6575): 1586- 93.

[3]	Hu Y , Lewandowski EM , Tan H , Zhang X , Morgan RT , Zhang X , et al. Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir. ACS Central Sci. 2023; 9 (8): 1658- 69.

[4]	Hirotsu Y , Kobayashi H , Kakizaki Y , Saito A , Tsutsui T , Kawaguchi M , et al. Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2. Med. 2023; 4 (11): 813- 24.e4.

[5]

Zuckerman NS , Bucris E , Keidar-Friedman D , Amsalem M , Brosh-Nissimov T . Nirmatrelvir resistance—de novo E166V/L50V mutations in an immunocompromised patient treated with prolonged nirmatrelvir/ritonavir monotherapy leading to clinical and virological treatment failure—a case report. Clin Infect Dis. 2024; 78 (2): 352- 5.

[6]	Iketani S , Mohri H , Culbertson B , Hong SJ , Duan Y , Luck MI , et al. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature. 2023; 613 (7944): 558- 64.

[7]	Unoh Y , Uehara S , Nakahara K , Nobori H , Yamatsu Y , Yamamoto S , et al. Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J Med Chem. 2022; 65 (9): 6499- 512.

[8]	Chen X , Huang X , Ma Q , Kuzmič P , Zhou B , Zhang S , et al. Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir. Nat Microbiol. 2024; 9 (4): 1075- 88.

[9]	Ma C , Tan H , Choza J , Wang Y , Wang J . Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays. Acta Pharm Sin B. 2021.

[10]	Sacco MD , Hu Y , Gongora MV , Meilleur F , Kemp MT , Zhang X , et al. The P132H mutation in the main protease of Omicron SARS-CoV-2 decreases thermal stability without compromising catalysis or small-molecule drug inhibition. Cell Res. 2022; 32 (5): 498- 500.

[11]	Noske GD , de Souza Silva E , de Godoy MO , Dolci I , Fernandes RS , Guido RVC , et al. Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease. J Biol Chem. 2023; 299 (3): 103004.